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tandem mass spectrometric (LC-MS/MS) method. Femoral blood concentration of cyclopropylfentanyl
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light of the current literature and under the exclusion that no other morphological findings could explain
the cause of death, contribution of cyclopropylfentanyl to death was proposed (polydrug use). Significant
postmortem concentration increases of cyclopropylfentanyl in femoral blood during 18h after the first
sampling were observed, thus indicating a relevant potential to undergo PMR. A central-to-peripheral
blood concentration ratio of 2.6 supports this. Consequently, the current case suggests that postmortem
cyclopropylfentanyl concentration should always be interpreted with care.
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Abstract 
A growing number of fatal overdoses involving opioid drugs, in particular involving fentanyl 
and its analogues, pose an immense threat to public health. Postmortem casework of forensic 
toxicologists in such cases is challenging, as data on pharmacodynamic and pharmacokinetic 
properties as well as reference values for acute toxicities and data on potential postmortem 
redistribution (PMR) mechanisms often do not exist. A fatal case involving cyclopropylfentanyl 
was investigated at the Zurich Institute of Forensic Medicine and the Zurich Forensic Science 
Institute; an unknown powder found at the scene was reliably identified as cyclopropylfentanyl 
by gas chromatography-infrared spectroscopy (GC-IR). Femoral blood samples were 
collected at two time points after death; 11 h postmortem (t1) and during the medico-legal 
autopsy 29 h after death (t2). At the autopsy, additional samples from the heart blood, urine 
and gastric content were collected. Cyclopropylfentanyl was quantified using a validated liquid 
chromatography-tandem mass spectrometric (LC-MS/MS) method. Femoral blood 
concentration of cyclopropylfentanyl at autopsy was 19.8 ng/mL (t1 = 15.7 ng/mL; heart blood 
concentration at autopsy = 52.4 ng/mL). In the light of the current literature and under the 
exclusion that no other morphological findings could explain the cause of death, contribution 
of cyclopropylfentanyl to death was proposed (polydrug use). Significant postmortem 
concentration increases of cyclopropylfentanyl in femoral blood during 18 h after the first 
sampling were observed, thus indicating a relevant potential to undergo PMR. A central-to-
peripheral blood concentration ratio of 2.6 supports this. Consequently, the current case 
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1. Introduction 
The use and misuse of new psychoactive substances (NPS) are a global problem with more 
than 800 substances having been reported to the United Nations Office on Drugs and Crimes 
(UNODC) Early Warning Advisory until December 2017 [1]. Synthetic cannabinoids and 
stimulants make up the largest fraction of these with 68 % reported substances, while synthetic 
opioids only account for 4 % of those reported in 2017. However, opioid drugs are extensively 
on the rise over the past years and, albeit small in number, pose an immense threat to public 
health [2]. This is reflected by a growing number of often fatal overdoses and the awareness 
that the opioid epidemic was declared a nationwide public-health emergency in the USA [3]. 
Fentanyl, being about 100 times more potent than morphine, is the strongest opioid licensed 
for medical use in humans for management of severe pain and during anesthesia [4]. As there 
has always been concern about its potential for abuse and dependence, fentanyl was placed 
under international control as a Schedule 1 substance in 1964 under the Single Convention 
on Narcotic Drugs of 1961 [4]. Shortly after the first synthesis of fentanyl in 1959, an increasing 
number of analogues have also started to appear. On the one hand during investigations as 
potential pharmaceuticals and on the other hand emerging on the illicit drug market, mis-sold 
as illicit heroin or in counterfeit medicines [4]. After a phase in the 1970s and 1980s where 
fentanyl and its analogues have been the cause for a number of accidental overdoses in the 
USA, recent years have seen an alarming come-back in both the USA and Europe [5]. Since 
2012, 28 new fentanyl analogues have been identified on the European drug market, eight of 
which were first reported in 2016 and further ten analogues were first identified during 2017 
[6]. One of these novel fentanyl analogues is cyclopropylfentanyl; formally reported on the 4th 
August, 2017 by the European Monitoring Centre for Drugs and Drug Abuse (EMCDDA) for 
the first time and temporary placed into Schedule 1 of the Controlled Substances Act by the 
Drug Enforcement Administration (DEA) in January 2018 [7, 8]. It differs from fentanyl by 
replacement of the propionamide group of fentanyl with a cyclopropanecarboxamide group; 
chemical structures of fentanyl and cyclopropylfentanyl are displayed in Fig. 1 [9]. 
Cyclopropylfentanyl has predominantly been detected in powder-form and to a lesser extent 
in form of liquid solutions (e.g. nasal spray solutions). It has also been identified in tablets, 
including fake benzodiazepines (e.g. Xanax®) and opioid analgesics (e.g. OxyContin®). The 
µ-opioid receptor agonist is suspected to show effects in humans, similar to other opioid 
analgesics such as euphoria, relaxation, analgesia, sedation, bradycardia, hypothermia and 
respiratory depression [7]. However, the general pharmacology and toxicology of 
cyclopropylfentanyl remains largely unstudied. This emphasizes the need to publish data on 
case reports with involvement of cyclopropylfentanyl in order to judge the concentration range 
of potential acute toxicities. Only very few publications reporting on postmortem or antemortem 
cyclopropylfentanyl concentrations and analytical challenges are currently available [10-12]. 
For reliable forensic case interpretation also the concept of postmortem redistribution has to 
be considered (PMR). This describes the mechanisms and processes that can alter drug 
concentrations artificially after death, caused by diffusion processes, degradation or drug neo-
formation [13]. To the best of our knowledge, there is currently no data on time-dependent 
postmortem variations available for cyclopropylfentanyl. However, given the structural 
similarity to fentanyl – a drug that has been shown to undergo extensive PMR – time-
dependent concentration changes of cyclopropylfentanyl seem to be likely [14-19]. The aim of 
the current work was to investigate time-dependent PMR of cyclopropylfentanyl in a single 
authentic case.  
 
2. Case history 
At around 9.00 am the dead body of a 39-year old male was found sitting on a sofa in a 
crouched position. A previous history of drug abuse was known; presumably regular nasal 
consumption of cocaine in previous years, but supposedly abstinent around time of death. 
According to the medical history, the deceased suffered from chronic pain in the region around 
the cervical spine. As a treatment, he took two tablets of OxyContin® daily (10 mg; one in the 
morning, one in the evening; active ingredient: oxycodone), ground with a pestle and mortar 
and nasally consumed. From the coffee table next to the deceased, a small plastic bag with 
an unknown white power was obtained. The external postmortem examination (at 11.30 am) 
revealed no injuries or signs of a violent cause of death. Time of death was estimated between 
6.5 to 8 h prior to the postmortem medical examination (i.e. between 3.30 and 5.00 am; 4.15 
am was set as the reference time of death-point for the purpose of further time interval 
calculations). Postmortem computed tomography (CT) imaging and autopsy revealed few 
non-specific signs of intoxication such as weak edema of the brain and blood congested lungs. 
Additionally, frothy fluid was found in the larynx and respiratory tract.  
 
3. Materials and methods 
3.1. Chemicals and reagents 
Methanolic solutions of cyclopropylfentanyl (0.1 mg/mL) and the deuterated internal standard 
(IS) fentanyl-d5 (0.1 mg/mL) were obtained from Chiron AS (Trondheim, Norway) and 
Lipomed (Arlesheim, Switzerland), respectively. Water was purified with a Purelab Ultra 
Millipore filtration unit (Labtech, Villmergen, Switzerland), acetonitrile of high-performance 
liquid chromatography (HPLC) grade was obtained from Fluka (Buchs, Switzerland) and ethyl 
acetate of pharmaceutical grade from Roth (Karlsruhe, Germany). All other chemicals used, 
were from Merck (Zug, Switzerland) and of the highest grade available. 
 
3.2. Postmortem samples 
Femoral venous blood samples were collected at two time points after death; 11 h postmortem 
(t1) and during the medico-legal autopsy 29 h after death (t2). At the autopsy, additional 
samples from the (whole) heart blood, urine and gastric content were collected. All samples 
were stored at -20 °C until analysis.  
 
3.3. Identification of unknown powder by GC-MS and GC-IR 
For gas chromatography coupled to electron ionization mass spectrometry (GC-EI-MS) 
analysis, the unknown powder sample was basified and dissolved in ethyl acetate (injection 
of 1 µL of an approximately 1 mg/mL ethyl acetate solution). EI mass spectra (scan range m/z 
30–650, after a solvent delay of 2 min) were obtained on an Agilent MSD 5975C (Agilent 
Technologies, Basel, Switzerland) equipped with an Agilent 7890A GC and an Agilent 7683B 
autosampler. Data handling was carried out with the corresponding workstation and Agilent 
MSD Chem-Station software. The carrier gas was helium at a constant flow rate of 1.3 mL/min. 
The injector (280 °C) was used in split mode (1:25). Transfer line and ion source were set at 
280 °C and 230 °C, respectively. Separations were carried out using a 30 m (length), 0.25 mm 
(internal diameter), 0.25 µm (film thickness) DB-5MS capillary column. The column 
temperature was programmed as follows: 80–320 °C with a heat rate of 15 °C/min; then held 
constant for 4 min at 320 °C; total run time was 20 min. The obtained data were compared to 
MS-Spectra of the European RESPONSE project as well as with data of the SWGDRUG 
monograph for cyclopropylfentanyl [20, 21]. 
For gas chromatography – infrared spectroscopy (GC-IR) analysis, the unknown powder 
sample was basified and dissolved in ethyl acetate (injection of 1 µL of an approximately 1 
mg/mL ethyl acetate solution) subjected to the DiscovIR spectrometer from Spectra Analysis 
(Marlborough, Massachusetts, USA) coupled with an Agilent 7890A GC and an Agilent 7693 
autosampler. The analysis was carried out using the same column type and the same GC 
conditions as for GC-EI-MS. Transfer line and restrictor were set to 300 °C. The disk was kept 
at -40 °C, the chamber at <10-4 Torr (~ <0.0133 Pa). Solid phase fourier transform – infrared 
spectroscope (FT-IR) spectra of the isolated cylopropylfentanyl were obtained for direct 
comparison with attenuated total reflection – infrared spectroscope (ATR-IR) spectra from the 
National Forensic Laboratory Slovenia from the European RESPONSE project [21].  
 
3.4. Routine systematic toxicological analysis 
Routine toxicological analysis was performed on femoral blood and urine collected at t2 
(autopsy samples). Initially, urine was screened by a cloned enzyme donor immunoassay 
(CEDIA®) for common drugs of abuse (opiates, cocaine, cannabis, amphetamines, 
methadone, barbiturates, benzodiazepines and lysergic acid diethylamide (LSD)), followed by 
an untargeted liquid chromatography – tandem mass spectrometry (LC-MS/MS) ion trap 
screening after simple dilution with mobile phase (Bruker amaZon ®; 
Maurer/Wissenbach/Weber database [22]). Femoral blood was additionally screened for 
ethanol and other volatile compounds by headspace GC flame ionization detection (HD-GC-
FID). Quantification of drugs in femoral blood was performed by LC-MS/MS using a previously 
validated method [23]. 
 
3.5. Sample preparation for PMR investigation 
Extractions of samples in triplicate were performed according to Staeheli et al. [24]. In short, 
20 µL body fluids were used to carry out a two-step liquid-liquid extraction (LLE) with butyl 
acetate/ethyl acetate (1:1, v/v); step 1 at pH 7.4 and step 2 at pH 13.5. After combination of 
the extracts, all samples were evaporated to dryness and reconstituted in 60 µL mobile phase. 
 
3.6. LC-MS/MS analysis of cyclopropylfentanyl 
Quantitative analysis was carried out on a Thermo Fisher Ultimate 3000 UHPLC system 
(Thermo Fisher, San Jose, CA, USA) coupled to a Sciex 5500 QTrap linear ion trap 
quadrupole mass spectrometer (Sciex, Darmstadt, Germany). Instrument settings were 
adapted from Staeheli et al. [24]. Multiple reaction monitoring (MRM) transitions for the 12C 
isotope of cyclopropylfentanyl were 349 -> 188 (quantifier), 349 -> 105 (qualifier) and 349 -> 
77 (qualifier). The quantifier 13C isotope transition was 350 -> 189. Fentanyl-d5 was used as 
IS. An LC gradient elution was performed using a Phenomenex (Aschaffenburg, Germany) 
Synergy Polar RP column (length x internal diameter: 100 x 2.0 mm, particle size: 2.5 µm) 
with 10 mM ammonium formate buffer in water containing 0.1 % (v/v) formic acid (pH 3.5, 
eluent A) and acetonitrile containing 0.1 % (v/v) formic acid (eluent B), according to Staeheli 
et al. [24]. The MS was controlled by Analyst® 1.6.3 software (Sciex) and quantitation was 
performed with MulitQuant® 3.0.2 software (Sciex). Cyclopropylfentanyl concentrations in the 
gastric content were calculated using the 13C calibration; concentrations of all other samples 
were calculated with the 12C calibration.  
The concentration difference between sampling point t1 and t2 for femoral blood was 
calculated as percentage difference, defining the mean concentration of triplicate 
measurements at t1 as 100 %. Statistical significance was tested using the student’s t-test 
(two-tailed distribution, p < 0.05). 
 
3.7. LC-MS/MS method validation 
The method to quantify cyclopropylfentanyl was validated in peripheral blood in terms of 
selectivity, calibration model, accuracy, precision, matrix effect, extraction efficiency and limits 
according to Peters et al. as a method for analysis of rare analytes [25].  
 
3.7.1. Selectivity 
To check for interfering signals with cyclopropylfentanyl or fentanyl-d5, six blank blood 
samples from different sources were analyzed. Two blank blood samples spiked with IS (zero 
samples) were analyzed to check for appropriate IS purity and presence of native analytes. 
 
3.7.2. Calibration model 
Calibrators were prepared in duplicates at ten concentration levels; 0.5, 1.0, 5.0, 10, 25, 50, 
100, 200, 350 and 500 ng/mL. For calibration levels 1-7 (0.5 – 100 ng/mL) the 12C isotope 
transition 349 -> 188 of cyclopropylfentanyl was used as quantifier; for calibration levels 6-10 
(50 – 500 ng/mL) the 13C isotope transition 350 -> 189 was used as quantifier. The regression 
lines for both calibrations were based on a linear calibration model with a 1/x weighting to 
compensate for heteroscedasticity. Back calculation of the mean calibrator concentrations 
should result in less than ± 20 % deviation to the theoretical concentrations. 
 
3.7.3. Accuracy and precision 
Six replicates of quality control (QC) samples at the concentration levels QC low (0.8 ng/mL), 
QC med (20 ng/mL), QC high (90 ng/mL) and QC high 13C (400 ng/mL) were prepared and 
analyzed on one day. Concentrations of QC low and QC med were calculated using the 12C 
calibration model (0.5 – 100 ng/mL) and concentration of QC high 13C was calculated using 
the 13C calibration model (50 – 500 ng/mL). QC high concentration was determined with both 
calibration models. Accuracy was calculated as the percent deviation of the mean calculated 
concentration at each QC level from the corresponding theoretical value and expressed as 
bias. A bias within ± 15 % of the nominal values was set as the acceptance criteria. Precision 
data was calculated as the relative standard deviation (RSD) within the QC levels and would 
be acceptable if within 15 % RSD.  
 
3.7.4. Matrix effect and extraction efficiency 
Matrix effect and extraction efficiency were evaluated at the concentration level of QC med 
using six blank blood samples from different sources according to the simplified approach 
described by Matuszewski et al. [26].  
 
3.7.5. Limits 
The limit of quantification (LOQ) was defined as the concentration of the lowest calibrator (0.5 
ng/mL) that had to meet the criteria of signal to noise 10:1 and a bias within ± 20 % of the 
target value. The limit of detection (LOD) was not systematically investigated. 
 
4. Results and discussion 
4.1. Identification of unknown powder by GC-MS and GC-IR 
It has recently been highlighted in the literature that it is an analytical challenge to distinguish 
cyclopropylfentanyl from its structural isomer crotonylfentanyl [11]. Based on identical mass 
spectral properties, the two isomers cannot be differentiated by MS methods and it is 
suggested to report the results as cyclopropyl-/crotonylfentanyl in casework [11, 12]. In 
accordance to this, the current GC-EI-MS analysis of the unknown powder revealed similar 
library match factors for cyclopropylfentanyl and crotonylfentanyl. However, Mallette et al. 
suggest that differences in the IR-spectra of the two isomers, enables to distinguish 
cyclopropylfentanyl from crotonylfentanyl [27]. IR spectra of well characterized reference 
material of both cyclopropylfentanyl and crotonylfentanyl were available from the European 
RESPONSE project [21]. The data obtained in the current case by FT-IR was consistent with 
the ATR-IR spectra of cyclopropylfentanyl, thus definite identification of the previously 
unknown powder could be accomplished. Following this, the current study can reliably report 
the occurrence of cyclopropylfentanyl, while excluding the occurrence of crotonylfentanyl. 
Original data are available contacting the corresponding author. 
 
4.2. Routine systematic toxicological analysis 
CEDIA® immunoassays in urine were positive for opiates and elevated for LSD (elevated 
means that the measured value was higher than a negative reference sample, but did not 
reach the LSD positive cut-off of 0.5 ng/mL). The LC-ion trap MS screening in urine revealed 
codeine, diphenhydramine, morphine, noscapine, oxycodone and zolmitriptan. Ethanol 
content in the femoral blood was found to be 1.27 g/kg (‰), other volatiles were not detected. 
Quantitative analysis in femoral blood resulted in 480 µg/L codeine, 1000 µg/L 
diphenhydramine, 14 µg/L morphine, 6.0 µg/L oxycodone and 4.5 µg/L zolmitriptan; 6-
monoacetylmorphine, dihydrocodeine, hydrocodone and hydromorphone gave negative 
results. A positive LSD immunoassay, without indication for LSD consumption in the case 
circumstances, is often taken as a hint for the intake of fentanyl or fentanyl analogues, based 
on potential cross-reactivity. In the current case, only an elevated immunoassay result was 
obtained and although this means the measured value was clearly higher than a negative 
reference sample, it did not reach the positive cut-off. Hence, this could not be classed as a 
clear indicator for the intake of fentanyl or a fentanyl analogue. The measured codeine and 
diphenhydramine concentrations in femoral blood were high, but upon comparison to 
Launiainen et al. they were not necessarily in the lethal range [28]. Within a case cohort of 
1903 postmortem cases with codeine detection, fatal concentrations were often considerable 
higher [28]. Additionally, diphenhydramine concentrations of up to 960 µg/L (within n = 57) 
were reported with no fatal poisonings within this case cohort [28]. Following this, assuming 
the intake of fixed dose combination tablets containing codeine, diphenhydramine and 
noscapine, an overdose of noscapine also seems unlikely. Under the exclusion that no other 
morphological findings could explain the cause of death, a combined intoxication with ethanol 
and cyclopropylfentanyl, with potential contribution of codeine and diphenhydramine, was 
discussed as the most likely cause of death.  
 
4.3. LC-MS/MS method validation 
As proposed by Peters et al., a one-day method validation used for a single case was carried 
out for the quantification of cyclopropylfentanyl [25]. No interfering signals were detected in 
blank blood and zero samples. For both the 12C and the 13C calibration, the linear regression 
model gave a R2 value of > 0.99. Back calculation of the calibrator concentrations resulted in 
less than ± 15 % deviation to the theoretical concentrations. Other validation results including 
accuracy, precision, matrix effect and extraction efficiency are given in Table 1. Calibrator 1, 
defined as the LOQ showed a signal-to-noise ratio of > 10:1 and a bias of 0.5 %. All validation 
parameters met the previously defined acceptance criteria. It is well known, that validation of 
a method solely in blood, while quantifying substances in other matrices as well, is generally 
not sufficient. However, in the current study, cyclopropylfentanyl was included in an existing, 
fully validated method that covers 83 analytes in 11 postmortem matrices (including the ones 
tested here) [24]. The former validation has shown, that accuracy and precision data for most 
analytes were within the specified ranges independent of the matrix, as long as an IS was 
used. As fentanyl-d5 was employed as IS in the current study, validation in femoral blood was 
deemed sufficient for quantitative analysis of cyclopropylfentanyl in four different matrices.  
 
4.4. Cyclopropylfentanyl analysis 
Femoral blood concentration of cyclopropylfentanyl at autopsy was 19.8 ng/mL (± 0.4 ng/mL 
across triplicate measurements). Only little reference data is available for interpretation of this 
postmortem concentration. Recently, 4 postmortem cases from the UK were reported with a 
mean cyclopropylfentanyl concentration in femoral blood of 23.7 ng/mL (range 16.6 – 28.9 
ng/mL) [11]. Cyclopropylfentanyl was deemed to have contributed to death in all 4 cases, so 
it seems likely that a similar contribution to death existed in the current case. Lower mean 
concentrations of cyclopropylfentanyl were reported from the USA; n = 32, mean = 15.2 ng/mL 
(± 11.9 ng/mL), range 1.4 – 43.3 ng/mL [10]. However analyzed blood was cardiac, iliac, 
femoral or peripheral blood from one time-point depending on the case availability, and no 
indication was given whether or not the cyclopropylfentanyl concentration was thought to have 
contributed to death. Generally it was observed that all submitted postmortem cases were also 
positive for other drugs, in addition to cyclopropylfentanyl [10]. This holds true for the current 
case as well, where various other opioids were also detected as detailed above. The 
advantage of the current work is the availability of additional matrices for analysis; namely 
samples from the heart blood, urine and gastric content. Distribution of cyclopropylfentanyl 
across the analyzed matrices is shown in Fig. 2. No postmortem urine concentrations have 
previously been reported, however recent antemortem data from Canadian substance use 
disorder clinics are available [29]. Depending on the province, mean urine concentrations of 
cyclopropylfentanyl of 24 ng/mL (range 1 – 3200 ng/mL), 6 ng/mL (range 3-27 ng/mL) and 16 
ng/mL (range 6 – 119 ng/mL) were detected in British Columbia (November 2017), Ontario 
(November 2017) and Ontario (February to October 2017), respectively [29]. In the current 
case we found a very low urine concentration of 6.6 ng/mL cyclopropylfentanyl (± 0.3 ng/mL 
across triplicate measurements). This seems surprising upon comparison to the antemortem 
data, as we can assume to find a considerable fraction of unchanged cyclopropylfentanyl in 
urine. A possible explanation would be a relative fast death after intake of the substance, 
therefore resulting in a short time window for drug distribution and accumulation in urine. A 
similar reason could also explain the very high quantified concentration in the gastric content 
(720 ng/mL ± 62 ng/mL across triplicate measurements; semiquantitative as outside the 
calibration range; total amount of gastric content: approx. 50 mL). As nasal application of 
cyclopropylfentanyl is assumed, this may have led to some swallowing of the powder or 
secretion into the acidic gastric content after absorption, leading to such high concentrations 
[30, 31].  
To the best of our knowledge, no time-dependent PMR data for cyclopropylfentanyl is 
available so far. A frequently used marker for the potential occurrence of PMR is a central-to-
peripheral blood concentration ratio (C/P-ratio) of > 1 [32]. Calculating such a ratio with the 
current concentration data, a C/P-ratio of 2.6 was found (at autopsy: femoral blood 
concentration = 19.8 ng/mL; heart blood concentration = 52.4 ng/mL). This indicates an 
extensive PMR-potential of cyclopropylfentanyl. However, a number of recent studies have 
shown that the C/P-ratio alone might not be a sufficient indicator for postmortem concentration 
changes as it omits time-dependency and a drugs’ physicochemical properties, such as Vd, 
pKa and protein binding affinity that are thought to highly influence PMR [14, 32-34]. Following 
this, it is crucial to look at the time-dependent femoral blood concentrations that are available 
in the current case (Fig. 3). Within 18 h and 10 min – the time difference between the first and 
second sampling point – a statistically significant 27 % concentration increase of 
cyclopropylfentanyl in femoral blood was observed (t-test; p < 0.05; t1 = 15.7 ng/mL; t2 = 19.8 
ng/mL). This supports the previous indication for extensive PMR of cyclopropylfentanyl. A 
limitation to the applied workflow is the fact that the very early postmortem phase could not be 
studied due to organizational reasons (i.e. the timeframe between death and admission to the 
institute). Although it is thought that PMR starts to occur in the first few minutes to hours after 
death, the applied method is a valuable tool to assess PMR. A specific redistribution 
mechanism cannot be proposed based on the current case data. However, butyrfentanyl was 
previously postulated to be redistributed by passive diffusion [30]. As cyclopropylfentanyl is 
structurally very similar to butyrfentanyl, a similar redistribution mechanism seems likely and 
would explain the observed concentration increases in femoral blood over time.  
 
5. Conclusion 
A fatal case involving cyclopropylfentanyl revealed significant postmortem concentration 
increases of cyclopropylfentanyl in femoral blood during 18 h after first sampling. This 
indicates a relevant potential for PMR, which is supported by a C/P-ratio of 2.6. Consequently, 
postmortem cyclopropylfentanyl concentration should be interpreted with great caution due to 
PMR processes. A systematic study covering more cases would be necessary to generate a 
universal statement on the PMR behavior of cyclopropylfentanyl.  
  
Tables 





Bias [%] Matrix 





Low 0.8 12C 5.3 -2.8   
Med 20  2.8 -4.9 110 ± 6.7 90 ± 8.7 
High 90  3.9 -5.9   
High 90 13C 3.2 1.5   








Fig. 2: Distribution of cyclopropylfentanyl across sampled matrices; displayed are the 
concentration means of triplicate measurements at autopsy (t2). 
 
 
Fig. 3: PMR of cyclopropylfentanyl in femoral blood, displayed as concentration vs. 
postmortem interval; each dot represents one sample of triplicate measurements; the mean 
concentrations at each sampling time point were connected with a line. 
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